Table 1 Overview of the groups for analysis of the proliferation time and the myogenic differentiation, using a mixed-effect model.

From: Selection of optimal human myoblasts based on patient related factors influencing proliferation and differentiation capacity

Examined factors

Proliferation time

Myogenic differentiation

Study population (n = 37)

Collected samples (n = 50)

Study population (n = 20)

Collected samples (n = 24)

Gender

 Male

12 (32.4%)

12 (24%)

7 (35%)

7 (29.7%)

 Female

25 (67.6%)

38 (76%)

13 (65%)

17 (70.8%)

Age (years)

 < 50

10 (27%)

15 (30%)

7 (35%)

9 (37.5%)

 ≥ 50

27 (73%)

35 (70%)

13 (65%)

15 (62.5%)

BMI (kg/m2)

 < 25

11 (29.7%)

15 (30%)

5 (25%)

6 (25%)

 ≥ 25

26 (70.3%)

35 (70%)

15 (75%)

18 (75%)

Chemotherapy

 Yes

18 (48.6%)

26 (52%)

7 (35%)

9 (37.5%)

 No

19 (51.4%)

24 (48%)

13 (65%)

15 (62.5%)

Radiation

 Yes

11 (29.7%)

11 (22%)

-

-

 No

26 (70.3%)

39 (78%)

-

-

Skeletal muscle type

 Rectus abdominis

23 (62.2%)

23 (46%)

12 (57.1%)

12 (50%)

 Pectoralis major

13 (35.1%)

14 (28%)

6 (28.6%)

6 (25%)

 Gracilis

5 (13.5%)

5 (10%)

2 (9.5%)

2 (8.3%)

 Vastus lateralis

4 (10.8%)

4 (8%)

2 (9.5%)

2 (8.3%)

 Latissimus dorsi

2 (5.4%)

2 (4%)

1 (4.8%)

1 (4.2%)

 Teres major

1 (2.7%)

1 (2%)

-

-

 Soleus

1 (2.7%)

1 (2%)

1 (4.8%)

1 (4.2%)

  1. The percentages regarding the skeletal muscle type do not add up to 100%, because in some cases, two muscle types from the same patient were used. Due to the low number of some muscle types, only samples from RA muscle and the PM muscle were used for differentiation analysis.
Back to article page